Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Comment by whisky11on Apr 27, 2021 9:03am
175 Views
Post# 33073185

RE:RE:Re: Buyout

RE:RE:Re: Buyout 011Peking]Sounds pretty interesting! Could someone explain how a buyout benefits ut as shareholders? Say we get bought out today when we're at 0.05. How much would we get for each share? Of course nobody knows for sure but someone may have a clue? Would we get as it is. 0.05 or x2, x10 etc?

whisky11: in case of buyout the premium is calculated in percentage, let's say 20,30 or 40% of existing stock price. Most likely we would get paid in the shares of the buyer company.
On the bright side rumours about buyout creates interest in the company, so the stock price goes up even before the deal is signed .
Most  companies don't like buyout, that's why they develop way of defending themselves ,they call it "poison pill", it's when targeted company start creating million's of shares and distributing it for free to "old shareholders" float of shares  rise and buying company doesn't make sense, it's too expensive.
In case of Claritas, stock price will be determined by the speed  we get to the market, not if someone buy us and change her name again.
It depends who the buyer is, but the risk is that you get paid in shares stagnated for last 20 years.
In my opinion the best solution is to get institutional investor to invest $45 million if the money are needed, second thing more important, go to the media and spread the news about  R-107
<< Previous
Bullboard Posts
Next >>